Abstract | INTRODUCTION: METHODS: Patients with RA (n = 133) were vaccinated with PPSV23. Patients were classified into TAC (n = 29), methotrexate (MTX) (n = 55), control (n = 35), and TAC/MTX (n = 14) treatment groups. We measured the concentrations of pneumococcal serotypes 6B and 23F by using an enzyme-linked immunosorbent assay and determined antibody functionality by using a multiplexed opsonophagocytic killing assay, reported as the opsonization index (OI), before and 4 to 6 weeks after vaccination. A positive antibody response was defined as at least a twofold increase in the IgG concentration or as at least a 10-fold increase in the OI. RESULTS:
IgG concentrations and OIs were significantly increased in all treatment groups after PPSV23 vaccination. The TAC treatment group appears to respond in a manner similar to that of the RA control group in terms of 6B and 23F serotype concentration and function. In contrast, the MTX group had the lowest immune response. Patients who received a combination of TAC and MTX (TAC/MTX) also had a diminished immune response compared with those who received TAC alone. CONCLUSIONS: TAC monotherapy does not appear to impair PPSV23 immunogenicity in patients with RA, whereas antibody production and function may be reduced when TAC is used with MTX. Thus, PPSV23 administration during ongoing TAC treatment should be encouraged for infection-prone TAC-treated patients with rheumatic diseases. TRIAL REGISTRATION: University Hospital Medical Information Network Clinical Trials Registry: UMIN000009566. Registered 12 December 2012.
|
Authors | Kiyoshi Migita, Yukihiro Akeda, Manabu Akazawa, Shigeto Tohma, Fuminori Hirano, Haruko Ideguchi, Ryutaro Matsumura, Eiichi Suematsu, Tomoya Miyamura, Shunsuke Mori, Takahiro Fukui, Yasumori Izumi, Nozomi Iwanaga, Hiroshi Tsutani, Kouichirou Saisyo, Takao Yamanaka, Shiro Ohshima, Takao Sugiyama, Yojiro Kawabe, Masao Katayama, Yasuo Suenaga, Akira Okamoto, Hisaji Ohshima, Yasumasa Okada, Kenji Ichikawa, Shigeru Yoshizawa, Kenji Kawakami, Toshihiro Matsui, Hiroshi Furukawa, Kazunori Oishi |
Journal | Arthritis research & therapy
(Arthritis Res Ther)
Vol. 17
Pg. 149
(Jun 03 2015)
ISSN: 1478-6362 [Electronic] England |
PMID | 26036592
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 23-valent pneumococcal capsular polysaccharide vaccine
- Antibodies, Bacterial
- Antirheumatic Agents
- Immunoglobulin G
- Pneumococcal Vaccines
- Tacrolimus
- Methotrexate
|
Topics |
- Aged
- Antibodies, Bacterial
(blood)
- Antirheumatic Agents
(therapeutic use)
- Arthritis, Rheumatoid
(drug therapy)
- Double-Blind Method
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Immunoglobulin G
(blood)
- Male
- Methotrexate
(therapeutic use)
- Middle Aged
- Pneumococcal Vaccines
(blood, immunology, therapeutic use)
- Tacrolimus
(therapeutic use)
|